CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.1067
-0.0063 (-5.56%)
At close: Dec 5, 2025

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
8.7710.733.952.840.43
Research & Development
7.365.473.72--
Other Operating Expenses
---0.060.14
Operating Expenses
1716.27.682.910.57
Operating Income
-17.5-16.2-7.68-2.91-0.57
Interest & Investment Income
0.070.030.142.84-
Other Non Operating Income (Expenses)
-0.034.530.24--
EBT Excluding Unusual Items
-17.46-11.64-7.3-0.07-0.57
Gain (Loss) on Sale of Investments
-----0
Other Unusual Items
2.753.340.01--
Pretax Income
-14.71-8.3-7.29-0.07-0.57
Income Tax Expense
---0.6-0.03
Net Income
-14.71-8.3-7.29-0.67-0.54
Preferred Dividends & Other Adjustments
34.482.78--36.16
Net Income to Common
-49.19-11.09-7.29-0.67-36.71
Shares Outstanding (Basic)
00-0-
Shares Outstanding (Diluted)
00-0-
EPS (Basic)
-98.71-434.46--59.38-
EPS (Diluted)
-98.71-434.46--59.38-
EBITDA
-17.18-15.76-7.21--
D&A For EBITDA
0.310.440.46--
EBIT
-17.5-16.2-7.68-2.91-0.57
Source: S&P Global Market Intelligence. Standard template. Financial Sources.